Back
Apellis Pharmaceuticals Vs. EyePoint Pharmaceuticals Industry Stock Comparison
Sell
48
APLS
Apellis Pharmaceuticals
Last Price:
30.76
Seasonality Move:
16.11%
Buy
61
EYPT
EyePoint Pharmaceuticals
Last Price:
8.94
Seasonality Move:
28.93%
Sell
48
Apellis Pharmaceuticals (APLS)
is a Sell
Is Apellis Pharmaceuticals a Buy, Sell or Hold?
- The current Apellis Pharmaceuticals [APLS] share price is $30.77. The Score for APLS is 48, which is 4% below its historic median score of 50, and infers higher risk than normal.
- APLS is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Buy
61
EyePoint Pharmaceuticals (EYPT)
is a Buy
Is EyePoint Pharmaceuticals a Buy, Sell or Hold?
- The current EyePoint Pharmaceuticals [EYPT] share price is $8.95. The Score for EYPT is 61, which is 22% above its historic median score of 50, and infers lower risk than normal.
- EYPT is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
APLS Stock Price Chart
What is Apellis Pharmaceuticals's stock price today?
-
The Apellis Pharmaceuticals share price today is $30.77
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and APLS is experiencing buying pressure, which is a positive indicator for future bullish movement.
EYPT Stock Price Chart
What is EyePoint Pharmaceuticals's stock price today?
-
The EyePoint Pharmaceuticals share price today is $8.95
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and EYPT is experiencing slight buying pressure.
APLS Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.14 | Sell |
| Relative Strength Index (14 RSI): | 59.23 | Buy |
| Chaikin Money Flow: | 2322513 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (26.9 - 29.12) | Buy |
| Bollinger Bands (100): | (28.55 - 38.61) | Sell |
EYPT Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.37 | Sell |
| Relative Strength Index (14 RSI): | 41.34 | Sell |
| Chaikin Money Flow: | 378625 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (9.4 - 11.84) | Sell |
| Bollinger Bands (100): | (8.13 - 10.51) | Sell |
APLS Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 27.97 | Buy |
| 20-day SMA: | 28.22 | Buy |
| 50-day SMA: | 29.11 | Buy |
| 200-day SMA: | 42.36 | Sell |
| 8-day EMA: | 28.48 | Buy |
| 20-day EMA: | 28.34 | Buy |
| 50-day EMA: | 29.88 | Buy |
| 200-day EMA: | 39.46 | Sell |
EYPT Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 9.31 | Sell |
| 20-day SMA: | 10.76 | Sell |
| 50-day SMA: | 9.77 | Sell |
| 200-day SMA: | 13.45 | Sell |
| 8-day EMA: | 9.35 | Sell |
| 20-day EMA: | 10.02 | Sell |
| 50-day EMA: | 9.94 | Sell |
| 200-day EMA: | 11.46 | Sell |
Apellis Pharmaceuticals Earnings Growth & APLS Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.09 per share, a decrease next quarter of $0.00 per share, an increase this year of $2.77 per share, and an increase next year of $0.81 per share.
EyePoint Pharmaceuticals Earnings Growth & EYPT Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.09 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.31 per share, and a decrease next year of $0.31 per share.
Apellis Pharmaceuticals Technical Analysis
| Nov 11 | Nov 12 | Nov 13 | Nov 14 | Nov 15 | Nov 18 | Nov 19 | Nov 20 | Nov 21 | Nov 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 11 | 12 | 13 | 14 | 15 | 18 | 19 | 20 | 21 | 22 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
EyePoint Pharmaceuticals Technical Analysis
| Nov 11 | Nov 12 | Nov 13 | Nov 14 | Nov 15 | Nov 18 | Nov 19 | Nov 20 | Nov 21 | Nov 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 11 | 12 | 13 | 14 | 15 | 18 | 19 | 20 | 21 | 22 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||